TopgOptions

CEMI Chembio Diagnostics upside potential

看多
NASDAQ:CEMI   None
Chembio Diagnostics' analysts are forecasting revenues of US$54m in 2021, a substantial 56% improvement in sales compared to the last year.

CEMI follows its bigger more profitable brother CODX in price action.
Depending on the future development of the global pandemic, those stocks could grow rapidly.

On 12/3/2020 Craig Hallum brokerage Upgraded the stock from Hold to Buy from $5.00 to $10.00 price target.

Because of the offering, I've lowered my price target to 5.5usd.

I`m looking forward to read your opinion about CEMI.


免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。